| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 Institute of Preventive Medicine and 2 Division of Biostatistics, Graduate Institute of Epidemiology, College of Public Health; Departments of 3 Internal Medicine and 4 Emergency Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan; and 5 Health Bureau of Lienchiang County, Matsu, Taiwan
Requests for reprints: Tony Hsiu-Hsi Chen, Institute of Preventive Medicine and Division of Biostatistics, Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Room 521, No. 17, Hsu-Chow Road, 100 Taipei, Taiwan. Phone: 886-2-33228021; Fax: 886-2-23587707. E-mail: stony{at}episerv.cph.ntu.edu.tw
Objective: The present study is done to assess the relative cost-effectiveness, optimal initial age, and interscreening interval between primary and secondary prevention strategies for gastric cancer.
Methods: Base-case estimates, including variables of natural history, efficacy of intervention, and relevant cost, were derived from two preventive programs targeting a high-risk population. Cost-effectiveness was compared between chemoprevention with 13C urea breath testing followed by Helicobacter pylori (H. pylori) eradication and high-risk surveillance based on serum pepsinogen measurement and confirmed by endoscopy. The main outcome measure was cost per life-year gained with a 3% annual discount rate.
Results: The incremental cost-effectiveness ratio (ICER) for once-only chemoprevention at age 30 years versus no screening was U.S. $17,044 per life-year gained. Eradication of H. pylori at later age or with a periodic scheme yielded a less favorable result. Annual high-risk screening at age of 50 years versus no screening resulted in an ICER of U.S. $29,741 per life-year gained. The ICERs of surveillance did not substantially vary with different initial ages or interscreening intervals. Chemoprevention could be dominated by high-risk surveillance when the initial age was older than 44 years. Otherwise, chemoprevention was more cost-effective than high-risk surveillance, either at ceiling ratios of U.S. $15,762 or up to U.S. $50,000. The relative cost-effectiveness was most sensitive to the infection rate of H. pylori and proportion of early gastric cancer in all detectable cases.
Conclusions: Early H. pylori eradication once in lifetime seems more cost-effective than surveillance strategy. However, the choice is still subject to the risk of infection, detectability of early gastric cancer, and timing of intervention. (Cancer Epidemiol Biomarkers Prev 2007;16(5):87585)
This article has been cited by other articles:
![]() |
Y-C Lee, A M-F Yen, J J Tai, S-H Chang, J-T Lin, H-M Chiu, H-P Wang, M-S Wu, and T H-H Chen The effect of metabolic risk factors on the natural course of gastro-oesophageal reflux disease Gut, February 1, 2009; 58(2): 174 - 181. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-C. Lee, J.-M. Liou, C.-Y. Wu, and J.-T. Lin Review: Eradication of Helicobacter pylori to prevent gastroduodenal diseases: Hitting more than one bird with the same stone Therapeutic Advances in Gastroenterology, September 1, 2008; 1(2): 111 - 120. [Abstract] [PDF] |
||||
![]() |
M. J. Blaser Understanding Microbe-Induced Cancers Cancer Prevention Research, June 1, 2008; 1(1): 15 - 20. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ramsey Gut Check: Can Cost-Effectiveness Analysis Help Eliminate Gastric Cancer in Asia? Cancer Epidemiol. Biomarkers Prev., May 1, 2007; 16(5): 873 - 874. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |